ANNEXON INC. - COMMON STOCK

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

18 Oct 2022 16:01:00 By Nasdaq GlobeNewswire

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

16 Sep 2022 16:01:00 By Nasdaq GlobeNewswire

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

17 Aug 2022 16:05:00 By Nasdaq GlobeNewswire

Annexon Biosciences Highlights Business and Portfolio Progress and Key Anticipated Milestones and Reports Second Quarter 2022 Financial Results

08 Aug 2022 16:01:00 By Nasdaq GlobeNewswire

Annexon Closes $130 Million Private Placement Extending its Operating Runway into the Second Half of 2025

11 Jul 2022 18:25:00 By Nasdaq GlobeNewswire

Annexon Announces $130 Million Private Placement Financing

08 Jul 2022 07:00:00 By Nasdaq GlobeNewswire

Annexon Biosciences Reports Phase 2 Clinical Trial Results Demonstrating Upstream Classical Complement Inhibition Associated with Clinical Benefit in Huntington’s Disease

07 Jun 2022 06:30:00 By Nasdaq GlobeNewswire

Annexon Biosciences to Present at the 2022 Jefferies Healthcare Conference

02 Jun 2022 06:30:00 By Nasdaq GlobeNewswire

Annexon Biosciences to Present Data Highlighting Novel Approach to Treating Complement-Driven Diseases at Upcoming Medical Meetings

01 Jun 2022 07:30:00 By Nasdaq GlobeNewswire

Annexon Biosciences Highlights Portfolio Progress and Key Anticipated Milestones, and Reports First Quarter 2022 Financial Results

09 May 2022 16:01:00 By Nasdaq GlobeNewswire

Annexon Biosciences to Participate in Upcoming May Investor Conferences

05 May 2022 06:30:00 By Nasdaq GlobeNewswire

Annexon Biosciences Completes Enrollment in ARCHER Phase 2 Trial of Novel C1q Inhibitor, ANX007, in Patients with Geographic Atrophy

07 Apr 2022 06:30:00 By Nasdaq GlobeNewswire

Annexon Biosciences to Participate in the 21st Annual Needham Virtual Healthcare Conference

04 Apr 2022 06:30:00 By Nasdaq GlobeNewswire

Annexon Biosciences to Present Preclinical Data Supporting Complement Inhibitor Programs for the Treatment of Guillain-Barré Syndrome and Huntington’s Disease at AAN 2022

03 Mar 2022 16:01:00 By Nasdaq GlobeNewswire

Annexon Biosciences Announces Program Highlights and Reports Fourth Quarter and Full Year 2021 Financial Results

01 Mar 2022 16:01:00 By Nasdaq GlobeNewswire

Annexon Biosciences to Participate in the Cowen 42nd Annual Healthcare Conference

28 Feb 2022 06:30:00 By Nasdaq GlobeNewswire

Annexon Biosciences Appoints Bettina M. Cockroft, M.D. to its Board of Directors

20 Jan 2022 06:30:00 By Nasdaq GlobeNewswire

Annexon Biosciences Reports Promising Interim Phase 2 Data Showing Improvement in Clinical Measures with ANX005 in Huntington’s Disease Following Six-Month Treatment

04 Jan 2022 16:05:01 By Nasdaq GlobeNewswire

Annexon Biosciences to Present at the 40th Annual J.P. Morgan Healthcare Conference

04 Jan 2022 06:30:00 By Nasdaq GlobeNewswire

Annexon Biosciences Announces Clinical and Preclinical Data Highlighting Potential of Complement-Targeting Programs at the 63rd ASH Annual Meeting & Exposition

13 Dec 2021 09:00:00 By Nasdaq GlobeNewswire